GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Prostate | ON | Recruiting
MIDAS-Prostate
Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer
Dr. Srinivas Raman
Start Date: November 1, 2022

NCT #: NCT05328505

SPONSOR: University Health Network, Toronto

INFO: https://www.clinicaltrials.gov/ct2/show/NCT05328505

CONTACT: 416-946-2320 

Renal | ON | Recruiting
CKFA115A12101
A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
Start Date: October 26, 2022

NCT #: NCT05544929

SPONSOR: Novartis Pharmaceuticals

INFO: https://clinicaltrials.gov/study/NCT05544929

CONTACT: 1-888-669-6682                                        

novartis.email@novartis.com

Other Canadian Centres:

Princess Margaret Cancer Centre (Toronto)

Renal | AB | Recruiting
MuST AKT & Pro00121297
Multidisciplinary Support to Access Living Donor Kidney Transplant (MuST AKT) (MuST AKT)
Dr. Shojai
Start Date: October 18, 2022

NCT #: NCT05459337

SPONSOR: University of Alberta

INFO: https://clinicaltrials.gov/study/NCT05459337

CONTACT: Dr. Selzler: aselzler@ualberta.ca

1-587-689-4921

Other Canadian Centres:

1. University of Alberta (Edmonton)

Prostate | ON | Recruiting
MOB-RT
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer (MOB-RT)
Dr. Rachel Glicksman
Start Date: July 18, 2022

NCT #: NCT05313815

SPONSOR: University Health Network, Toronto

INFO: https://clinicaltrials.gov/ct2/show/NCT05313815

CONTACT:  416-946-4483

Bladder | ON | Recruiting
D9450C00001
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
AstraZeneca
Start Date: July 7, 2022

NCT #: NCT05397171

SPONSOR: AstraZeneca

INFO: https://clinicaltrials.gov/ct2/show/NCT05397171?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=15

CONTACT:  1-877-240-9479

OTHER CANADIAN CENTRES:

1. The Ottawa Hospital

2. Mount Sinai Hospital (Toronto)

Renal | ON | Recruiting
MOHCCN-O
Marathon of Hope Cancer Centres Network Study for Ontario
University Health Network. Collaboration with PMH, OICR and Terry Fox Research Institute
Start Date: June 13, 2022

NCT #: NCT05403177

SPONSOR:  University Health Network

INFO: https://clinicaltrials.gov/ct2/show/NCT05403177?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=17

CONTACT: 

Sophie Cooke, MSc: 416-946-4501 x 3486

OTHER CANADIAN CENTRES:

Princess Margaret Cancer Centre (Toronto)               

Bladder | ON | Recruiting, by invitation only
ROSY-D
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D)
Start Date: April 19, 2022

NCT #: NCT05303532

SPONSOR: AstraZeneca

INFO:  https://clinicaltrials.gov/ct2/show/NCT05303532?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=5

CONTACT: Southlake Regional Health Centre (Newmarket): 905-895-4521 (Canadian Site)

OTHER CANADIAN CENTRES:

1. Southlake Regional Health Centre (Newmarket): 905-895-4521

 

Bladder | QC | Recruiting
BicaBCa
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa)
Dr. Paul Toren
Start Date: April 14, 2022

NCT #: NCT05327647

SPONSOR: CHU de Quebec-Universite Laval in Collaboration with Canadian Institute of Health Research (CIHR)

INFO: https://classic.clinicaltrials.gov/ct2/show/NCT05327647

CONTACT: 

Paul.Toren@crchudequebec.ulaval.ca (CHUQ)     418-525-4444 ext 17064                                            

wassim.kassouf.med@ssss.gouv.qc.ca                  514-934-8246                                                                        

jean-baptiste.lattouf.med@ssss.gouv.qc.ca

Other Canadian Centres:

CHU de Québec-Université (Laval): Dr. P. Toren                                    

McGill University Health Centre (Montreal: Dr.Wassim Kassouf                            

Centre Hospitalier de l'Université De Montréal (CHUM): Dr. Jean-Baptiste Lattouf
 

Prostate | NS, ON, QC | Recruiting
CAPItello280
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280
Start Date: March 25, 2022

NCT #: NCT05348577

SPONSOR: AstraZeneca

INFO: https://clinicaltrials.gov/study/NCT05348577

CONTACT: information.center@astrazeneca.com

Other Canadian Centers:

1. Sunnybrook Health Sciences Centre (Toronto). 2. QE11 Nova Scotia Health (Halifax). 3. Lakeridge Health (Oshawa). 4. Princess Margaret Cancer Centre (Toronto). 5. Jewish General Hospital (Montreal). 6. Hopital Fleurimont (Sherbrooke)

Prostate | QC | Recruiting
PROSTEP-002
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
Dr. Frédéric Pouliot
Start Date: March 22, 2022

NCT #: NCT04655365

SPONSOR: CHU de Quebec-Universite Laval in collaboration with Astellas

INFO: https://clinicaltrials.gov/ct2/show/NCT04655365

CONTACT:  418 525-4444 ext 20417

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy